X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Medison will commercialize Libtayo (cemiplimab), a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells, in select European markets and additional markets around the world.
Lead Product(s): Cemiplimab
Therapeutic Area: Oncology Product Name: Libtayo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 08, 2024
Details:
The new agreement will allow Alnylam to utilize Medison's unique multi-regional platform to ensure that Alnylam's innovative RNAi therapeutics, such as ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran) are made available across additional countries in Europe.
Lead Product(s): Givosiran Sodium
Therapeutic Area: Genetic Disease Product Name: Givlaari
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alnylam Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration March 09, 2023
Details:
Kimmtrak (tebentafusp) is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. Tebentafusp specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma.
Lead Product(s): Tebentafusp
Therapeutic Area: Oncology Product Name: Kimmtrak
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Immunocore
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 09, 2022
Details:
Idefirix® (imlifidase) becomes the first and only product reimbursed for the desensitization of highly sensitized patients waiting for a kidney transplant in Poland.
Lead Product(s): Imlifidase
Therapeutic Area: Immunology Product Name: Idefirix
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Hansa Biopharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
Under the agreement with Albireo, Medison aims to commercialize Odevixibat in Canada and Israel, for the treatment of patients with cholestatic liver diseases. Odevixibat is approved in Europe as Bylvay® for the treatment of progressive familial intrahepatic cholestasis.
Lead Product(s): Odevixibat
Therapeutic Area: Genetic Disease Product Name: Bylvay
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Albireo Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 16, 2022
Details:
Efgartigimod is approved in the United States as VYVGART® for the treatment of adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and in Japan for the treatment of adults with gMG.
Lead Product(s): Efgartigimod
Therapeutic Area: Immunology Product Name: Vyvgart
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Argenx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 06, 2022
Details:
The multi-territorial agreement to help seek regulatory authorization and commercialize Immunocore's KIMMTRAK® (tebentafusp -tebn) for the treatment of unresectable or metastatic uveal melanoma, a rare and aggressive form of melanoma that affects the eye.
Lead Product(s): Tebentafusp-tebn
Therapeutic Area: Oncology Product Name: Kimmtrak
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Immunocore
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 23, 2022
Details:
BRUKINSA is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) discovered by BeiGene scientists that is currently being evaluated globally in a broad clinical program as a monotherapy and in combination with other therapies to treat various B-cell malignancies.
Lead Product(s): Zanubrutinib
Therapeutic Area: Oncology Product Name: Brukinsa
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: BeiGene
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2022
Details:
Medison to help seek regulatory authorization and commercialize Immunocore’s tebentafusp (IMCgp100), for the treatment of patients with metastatic uveal melanoma, in Canada, twenty markets across Central Eastern Europe and Israel.
Lead Product(s): Tebentafusp
Therapeutic Area: Oncology Product Name: IMCgp100
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Immunocore
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 18, 2021
Details:
IMCIVREE was approved on November 2020 by the U.S.FDA for chronic weight management in adults and pediatric patients 6 years of age and older with obesity due to POMC, proprotein convertase subtilisin/kexin type 1 (PCSK1) or LEPR deficiency confirmed by genetic testing.
Lead Product(s): Setmelanotide Acetate
Therapeutic Area: Genetic Disease Product Name: Imcivree
Highest Development Status: ApprovedProduct Type: Peptide
Recipient: Rhythm Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 22, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
